Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘ESMO17’

While there continues to be an almost obsessive and fervant attention and focus on cancer immunotherapy, let’s not forget that chemotherapy and/or targeted therapy combinations are still the standard of care in many cases.

Plaza de Cibeles, Madrid

There are also numerous pipeline trials still ongoing and especially in the case of diseases with a low number of somatic mutations, other approaches may continue to have more utility and clinical benefit than say, monotherapy with checkpoint blockade.

So what’s in store in our second ESMO17 Preview series?

Following on from the Top 5 IO abstracts earlier this week, next up in the spotlight is the Targeted Therapy Top 5 Selections…

To learn more insights on this intriguing topic, subscribers can log-in or you can gain access to BSB Premium Content.

This content is restricted to subscribers

 

 

It’s that time of the year again – time to highlight key events and talks at the upcoming European Society of Medical Oncology (ESMO) meeting held in Madrid next month.

Over the next two days, we’re going to take a look at five key IO trials (today) and five targeted therapy studies (tomorrow) that are being presented at ESMO.

In short, what should readers know about these oral presentations for greater context, why are they important, and what should you be looking for?

We will cover the hidden gems from the poster halls to watch out for in a separate future post.

To learn more about our latest insights, subscribers can log-in or you can purchase access to BSB Premium Content.

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!